AstraZeneca Plc (LON: AZN), a global, science-led biopharmaceutical company, announced on Tuesday changes to certain of its board committees.

Under these changes, effective 1 July 2018, Nazneen Rahman will become permanent chairman of the science committee. Professor Rahman joined the science committee on her appointment as a director on 1 June 2017 and has been interim chairman of the committee since November 2017.

Also, effective 30 June 2018, Shriti Vadera will step down as a member of the audit committee. Vadera has informed the board that she will retire as a director by 31 December 2018. With effect from 1 November 2018, Deborah DiSanzo will become a member of the audit committee.

In addition, effective 1 July 2018, Sheri McCoy will become a member of the remuneration committee, while Nazneen Rahman will become a member of the nomination and governance committee.

AstraZeneca focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas of Oncology, Cardiovascular, Renal & Metabolism and Respiratory. The company is also selectively active in the areas of autoimmunity, neuroscience and infection.